



Formation

Founded April 2020 as a collaboration among leaders in genomics, bioinformatics and cancer from Columbia University (New York) and Samsung Medical Center (Seoul).

Based in New York, NY
 Delaware corporation
www.genotwin.com

Founders:

Raul Rabadan, Chief Scientific Advisor
 Oliver Elliott, CEO
 Dohyun Nam, Advisor
 Jae-Hoon Song, Advisor
 Seunghee Ham, Advisor

Funding

Raised to date: \$1.2 mil
 Seeking: \$5 mil for growth/ adoption activities related to hiring key staff, conducting targeted pilots and developing sales.

Recent Highlights

- Conducted successful proofs of concept on multiple academic and commercial data sets
- Established Asian partnerships related to key applications:
 - AIMEDBio, Seoul – precision-treatment of cancer
 - Avatamed, Singapore – sequencing and public health surveillance
- Finalizing pathogen surveillance collaborations with one of U.S.'s largest sampling companies


Who We Are

GenoTwin is a next-generation genomic analytics platform whose mission is to weave the power of genomics into clinical practice, public health, and drug discovery to dramatically enhance patient and community health outcomes.

Challenge and Solution

Common diagnostic tests yield little information beyond the positive or negative presence of one or a few pathogens. We combine genomic analysis, computational biology, and AI to extract dramatically deeper insights from these samples to address a much wider range of therapeutic needs.

Specifically, our solutions provide a holistic view of disease to enhance evaluation and treatment:




- Detects all expressed pathogens – existing and novel – and the presence of co-infections
- Determines their geo-provenance and strain
- Assesses host immune status
- Informs potential host severity/clinical course
- Indicates drug effectiveness and resistance

Market

Prior to SARS-CoV-2, the market for next generation sequencing services (NGS) was projected to grow at least 20% annually over the next several years. We believe SARS-CoV-2 significantly accelerates market adoption.

- Services within NGS is estimated at \$820 mil (20%) of the market
- Primary markets: Public Health, Defense, Infectious Disease Physicians, Hospitals, Pharmaceuticals



Source: Global Market Insights, April 2019

Model and Approach

GenoTwin initially will target those opportunities within infectious disease diagnostics and public health surveillance where our platform delivers the most significant value. We will design products for a high level of scale and user experience and will leverage our partnerships to support initial client acquisition. This foundation will provide a rich set of data and capabilities to enter additional markets and support drug discovery/precision medicine in the future.

Leadership Team

Our core team possesses deep expertise and experience across scientific, business, and technical areas.



Oliver Elliott, CEO

Bioinformatics and software development, Department of Systems Biology, Columbia University



Raul Rabadan PhD, Chief Scientific Advisor

Professor, Systems Biology and Biomedical Informatics and Director of the Mathematical Genomics Program, Columbia University



Dohyun Nam, Science and Business Advisor

CEO & Founder of AimedBio, Professor of Neurosurgery, Samsung Medical Center



Reuben Danzing, CFO and Business Planning

Founder, FutureSet Strategy LLC, focusing on growth and adoption strategy, measurement, and modeling
 Certified Public Accountant



Seunghee Ham, Advisor

Legal, corporate governance and operations
 In-house counsel, Moody's



Hong-Boon Toh, Business Development - Asia

Business Development and Commercial Operations, Avatamed

Scientific Advisory Board

We have recruited a multi-disciplinary Scientific Advisory Board of distinguished scientists, including several members of the National Academy of Sciences:

Arnold Levine (Professor, Institute for Advanced Study, Princeton); **Thomas Shenk** (Elkins Professor of Life Sciences, Molecular Biology Department, Princeton University); **Stephen Goff** (Higgins Professor of Microbiology & Immunology and Biochemistry & Molecular Biophysics, Stanford); **Stacey Schultz-Cherry** (Deputy Director, WHO Collaborating Centre for Studies on Ecology of Influenza in Animals and Birds and Faculty Member, Infectious Disease at St Jude Medical); **Dan Notterman** (Professor, Princeton University).

Publications. Our core science and bioinformatics team has published numerous high impact articles exploring the intersection of genomics with infectious disease, cancer, and immunity. A sample is as follows while additional ones can be found on our website www.genotwin.com:

Pathogen & Immune Characterization

Understanding Coronavirus (Understanding Life)

Raul Rabadan, Cambridge University Press 2020

Geographic Dependence, Surveillance, and Origins of the 2009 Influenza A (H1N1) Virus

The New England Journal of Medicine, 2009

arcasHLA: High-resolution HLA Typing from RNAseq

Bioinformatics, 2020

Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma

PLOS Pathogens, 2015

Network analysis of global influenza spread

PLOS Computational Biology, 2010

Cancer Genomic & Immune Characterization

Immune and Genomic Correlates of Response to Anti-PD-1 Immunotherapy in Glioblastoma

Nature Medicine, 2019

Pharmacogenomic Landscape of Patient-derived Tumor Cells Informs Precision Oncology Therapy

Nature Genetics, 2018

Spatiotemporal genomic architecture informs precision oncology in glioblastoma

Nature Genetics, 2017

Clonal evolution of glioblastoma under therapy

Nature Genetics, 2016

BRAF mutations in Hairy Cell Leukemia

New England Journal of Medicine, 2011